|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 17.40 0.00 0.00%
Mr. Guido Oelkers, Ph.D. was appointed President and Chief Executive Officer at Swedish Orphan Biovitrum AB effective as of May 22, 2017. Guido Oelkers joined Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis, where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda. Guido Oelkers holds a Ph.D. in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He completed his postgraduate studies in Economics at London School of Economics and Political Science.
Age: 51 CEO Since 2017
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 6.58 %
which means that it generated profit of $6.58 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 14.88 %
meaning that it generated $14.88 on every $100 dollars invested by stockholders.
The company has accumulated 64.15 M in total debt with debt to equity ratio (D/E) of 7.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.78 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.